VIDEO: Data on hepatic arterial infusion pump chemotherapy creates buzz
Click Here to Manage Email Alerts
In this video, Laleh Melstrom, MD, MS, discusses research on the use of hepatic arterial infusion pump chemotherapy in patients with advanced intrahepatic cholangiocarcinoma presented at ASCO Gastrointestinal Cancers Symposium.
In the multicenter phase 2 trial, researchers found that patients who received a hepatic arterial infusion pump (HAIP) with systemic chemotherapy experienced an OS of 22 months and a 3-year OS of 28.6%, with a PFS of 10 months.
"That data is clearly markedly better than our historical data from the ABC trial at 3-year overall survival of only 2.8%," Melstrom, a surgical oncologist at City of Hope, said.
"This study, I would say, rendered the greatest buzz in our session," Melstrom said.
Reference:
- Franssen S, et al. Abstract 433. Presented at: ASCO Gastrointestinal Cancers Symposium; Jan. 18-20, 2024; San Francisco.
Collapse
Healio Interviews
Click Here to Manage Email Alerts